Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytarabine in newly diagnosed adult Langerhans cell histiocytosis
NCT04121819Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine in Langerhans cell histiocytosis (LCH), sponsored by Peking Union Medical College Hospital. Primary endpoint: Event-free survival at 5 years. Status: unknown.
02
Drugs
cytarabine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT04121819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121819.